FDA panel backs Moderna's first-of-its-kind mRNA flu vaccine
FDA advisors have backed Moderna’s new mFlusiva mRNA flu vaccine, targeting older adults ahead of the upcoming winter flu season.
New mRNA technology for influenza prevention
The United States Food and Drug Administration (FDA) is currently evaluating Moderna's latest medical advancement, a vaccine known as mFlusiva. This shot marks a significant shift in influenza prevention, utilising messenger RNA (mRNA) technology—the same platform used in several highly effective COVID-19 vaccines developed in recent years.
The advisory panel's support comes at a critical time as health officials prepare for the annual winter flu season. Moderna is currently seeking full approval for the vaccine to be used in adults aged between 50 and 64 years to provide an additional layer of protection for this demographic.
Targeting older populations
In addition to the push for full approval in the 50-64 age bracket, the company is seeking authorisation for the vaccine's use in individuals aged 65 and older. This authorisation would allow for broader availability while Moderna conducts further necessary testing to ensure long-term efficacy and safety for the oldest and most vulnerable demographic.
The development of an mRNA-based flu vaccine represents a potential leap forward in how seasonal viruses are addressed. By leveraging this technology, researchers hope to offer more rapid updates to vaccine compositions, allowing them to match evolving viral strains more effectively than traditional methods.
